These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

535 related articles for article (PubMed ID: 26952309)

  • 1. Early response to inhaled bronchodilators and corticosteroids as a predictor of 12-month treatment responder status and COPD exacerbations.
    Calverley PM; Postma DS; Anzueto AR; Make BJ; Eriksson G; Peterson S; Jenkins CR
    Int J Chron Obstruct Pulmon Dis; 2016; 11():381-90. PubMed ID: 26952309
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Long-term health-related quality-of-life and symptom response profiles with arformoterol in COPD: results from a 52-week trial.
    Donohue JF; Bollu VK; Stull DE; Nelson LM; Williams VS; Stensland MD; Hanania NA
    Int J Chron Obstruct Pulmon Dis; 2018; 13():499-508. PubMed ID: 29440887
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy and safety of fixed-dose combinations of aclidinium bromide/formoterol fumarate: the 24-week, randomized, placebo-controlled AUGMENT COPD study.
    D'Urzo AD; Rennard SI; Kerwin EM; Mergel V; Leselbaum AR; Caracta CF;
    Respir Res; 2014 Oct; 15(1):123. PubMed ID: 25756831
    [TBL] [Abstract][Full Text] [Related]  

  • 4. AZD9668, a neutrophil elastase inhibitor, plus ongoing budesonide/formoterol in patients with COPD.
    Kuna P; Jenkins M; O'Brien CD; Fahy WA
    Respir Med; 2012 Apr; 106(4):531-9. PubMed ID: 22197578
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of budesonide/formoterol pMDI on COPD exacerbations: a double-blind, randomized study.
    Sharafkhaneh A; Southard JG; Goldman M; Uryniak T; Martin UJ
    Respir Med; 2012 Feb; 106(2):257-68. PubMed ID: 22033040
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A score to predict short-term risk of COPD exacerbations (SCOPEX).
    Make BJ; Eriksson G; Calverley PM; Jenkins CR; Postma DS; Peterson S; Östlund O; Anzueto A
    Int J Chron Obstruct Pulmon Dis; 2015; 10():201-9. PubMed ID: 25670896
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of budesonide/formoterol pressurized metered-dose inhaler on exacerbations versus formoterol in chronic obstructive pulmonary disease: The 6-month, randomized RISE (Revealing the Impact of Symbicort in reducing Exacerbations in COPD) study.
    Ferguson GT; Tashkin DP; Skärby T; Jorup C; Sandin K; Greenwood M; Pemberton K; Trudo F
    Respir Med; 2017 Nov; 132():31-41. PubMed ID: 29229103
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Maintenance therapy with budesonide and formoterol in chronic obstructive pulmonary disease.
    Calverley PM; Boonsawat W; Cseke Z; Zhong N; Peterson S; Olsson H
    Eur Respir J; 2003 Dec; 22(6):912-9. PubMed ID: 14680078
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Functional respiratory imaging assessment of budesonide/glycopyrrolate/formoterol fumarate and glycopyrrolate/formoterol fumarate metered dose inhalers in patients with COPD: the value of inhaled corticosteroids.
    van den Berge M; De Backer J; Van Holsbeke C; De Backer W; Trivedi R; Jenkins M; Dorinsky P; Aurivillius M
    Respir Res; 2021 Jul; 22(1):191. PubMed ID: 34210340
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Reduction in clinically important deterioration in chronic obstructive pulmonary disease with aclidinium/formoterol.
    Singh D; D'Urzo AD; Chuecos F; Muñoz A; Garcia Gil E
    Respir Res; 2017 May; 18(1):106. PubMed ID: 28558833
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The association of lung function and St. George's respiratory questionnaire with exacerbations in COPD: a systematic literature review and regression analysis.
    Martin AL; Marvel J; Fahrbach K; Cadarette SM; Wilcox TK; Donohue JF
    Respir Res; 2016 Apr; 17():40. PubMed ID: 27084761
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Budesonide added to formoterol contributes to improved exercise tolerance in patients with COPD.
    Worth H; Förster K; Eriksson G; Nihlén U; Peterson S; Magnussen H
    Respir Med; 2010 Oct; 104(10):1450-9. PubMed ID: 20692140
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Budesonide/formoterol via Turbuhaler® versus formoterol via Turbuhaler® in patients with moderate to severe chronic obstructive pulmonary disease: phase III multinational study results.
    Fukuchi Y; Samoro R; Fassakhov R; Taniguchi H; Ekelund J; Carlsson LG; Ichinose M
    Respirology; 2013 Jul; 18(5):866-73. PubMed ID: 23551359
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Bronchodilator Efficacy of a Single-Dose 12/400-µg Formoterol/Budesonide Combination as a Dry Powder for Inhalation Delivered by Discair
    Yildiz P; Bayraktaroglu M; Gorgun D; Yuksel K
    Clin Drug Investig; 2019 Oct; 39(10):991-1001. PubMed ID: 31332649
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy of budesonide/glycopyrronium/formoterol metered dose inhaler in patients with COPD: post-hoc analysis from the KRONOS study excluding patients with airway reversibility and high eosinophil counts.
    Muro S; Sugiura H; Darken P; Dorinsky P
    Respir Res; 2021 Jun; 22(1):187. PubMed ID: 34182998
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The efficacy of aclidinium/formoterol on lung function and symptoms in patients with COPD categorized by symptom status: a pooled analysis.
    Miravitlles M; Chapman KR; Chuecos F; Ribera A; Gil EG
    Int J Chron Obstruct Pulmon Dis; 2016; 11():2041-53. PubMed ID: 27621610
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy and tolerability of budesonide/formoterol added to tiotropium compared with tiotropium alone in patients with severe or very severe COPD: A randomized, multicentre study in East Asia.
    Lee SD; Xie CM; Yunus F; Itoh Y; Ling X; Yu WC; Kiatboonsri S
    Respirology; 2016 Jan; 21(1):119-27. PubMed ID: 26394882
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy of revefenacin, a long-acting muscarinic antagonist for nebulized therapy, in patients with markers of more severe COPD: a post hoc subgroup analysis.
    Donohue JF; Kerwin E; Barnes CN; Moran EJ; Haumann B; Crater GD
    BMC Pulm Med; 2020 May; 20(1):134. PubMed ID: 32393215
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy and safety of budesonide/formoterol via a dry powder inhaler in Chinese patients with chronic obstructive pulmonary disease.
    Zhong N; Zheng J; Wen F; Yang L; Chen P; Xiu Q; Yao W; Sun T; Zhao Z; Shen H; Shi Y; Lin J; Li Q
    Curr Med Res Opin; 2012 Feb; 28(2):257-65. PubMed ID: 22046961
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy and safety of aclidinium/formoterol versus salmeterol/fluticasone: a phase 3 COPD study.
    Vogelmeier C; Paggiaro PL; Dorca J; Sliwinski P; Mallet M; Kirsten AM; Beier J; Seoane B; Segarra RM; Leselbaum A
    Eur Respir J; 2016 Oct; 48(4):1030-1039. PubMed ID: 27492833
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 27.